ESSA Pharma Inc (TSX-V: EPI;Nasdaq: EPIX), a Canada-based pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer, has granted incentive stock options to directors and officers, employees and consults of the Corporation to purchase up to an aggregate of 238,000 common shares in the capital of the Corporation, it was reported on Friday.

Such stock options will vest in 48 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date.

The stock options are exercisable on or before 8 February 2029 at the price of USD3.81 per common share and are offered in accordance with the policies of the TSX Venture Exchange and the terms and conditions of the corporation's stock option plan.